Pharma BD Deal Intelligence
Cephalon, Inc. to buy generic firm Mepha Ltd. for $590 million in a move to expand internationally and diversify.
Commentary framed the Mepha purchase as defensive diversification ahead of Cephalon's 2012 Provigil patent cliff, with skepticism about a US specialty pharma…
Cephalon completed the Mepha acquisition on April 9, 2010 at CHF 662.4M (~US$615.4M); deal diversified Cephalon's business mix, doubled international revenue…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Cephalon agreed to acquire Swiss-based Mepha AG for CHF 622.5M (~$590M announced, $615.4M actual close). Adds emerging-markets branded generics. Closed April 2010.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / Mepha AG (this deal) | 2010 | $615M | 23 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Cephalon Inc. / Cell Therapeutics, Inc. | 2005 | $70M | 74 |
| Cephalon Inc. / Anesta Corp. | 2001 | $444M | 65 |
| Cephalon Inc. / Anesta Corp. | 2000 | $444M | 64 |
← Browse all deals · How we score deals
More: 2010 deals · Cephalon Inc. deals · Multiple deals